Blake Powers, CEO, Medigi, discusses how face-to-face collaboration and streamlined commercialization strategies are helping ...

Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.

Led by Brett Casper, a senior principal at Blue Fin Group, his agenda revolved around outlining the evolving orthodoxies for commercialization of ORD, CGT, and precision medicine; commercialization ...

Tiara Green, president, Accessia Health, highlights key themes from the upcoming discussion on how health equity, literacy, and social determinants are reshaping patient care—especially for those with ...

A session dives into the trends surrounding specialty drugs and therapies, along with providing an overview of the drug development landscape.

Investment includes $1.5 billion in capital expenditures to expand manufacturing and $500 million dedicated to R&D focused on ...

The Regeneron SVP details the company’s approach to reaching oncology patients across the planet.

Approval of penpulimab-kcqx marks the company’s US regulatory debut and introduces a new immunotherapy option for advanced ...

CMS’ draft guidance on real-world data study protocols marks a significant move toward transparency and rigor in Medicare ...

Ferring Pharmaceuticals announced strong performance results for 2024, with one part of the announcement standing out as ...

Chris Springate, CEO, ARC Medical, discusses how postoperative adhesions continue to cause chronic pain, infertility, and ...

The chaotic tariff situation is forcing pharma companies to prepare for multiple outcomes. While supply chain interruptions ...